Pushkang received tens of millions of yuan in round B financing

Zhejiang Pushkang Biotechnology Co., Ltd., a microfluidic coagulation enterprise, has completed tens of millions of yuan B round financing, led by bioVenture, joined by Sinopharm Capital, and Foursquare Capital. Optimas Capital serves as the exclusive financial adviser.

Zhejiang Pushkang Biotechnology Co., Ltd., a microfluidic coagulation enterprise, has completed tens of millions of yuan B round financing, led by bioVenture, joined by Sinopharm Capital, and Foursquare Capital. Optimas Capital serves as the exclusive financial adviser.

According to reports, this round of funds will be used for the development, production capacity expansion and marketing of microfluidic coagulation new products.

Established in 2014, Pushkang specializes in the field of microfluidic coagulation.

Its core positioning is mainly reflected in the use of centrifugal microfluidic as a technical platform, combined with the function of micro-level whole blood separation, to explore the medical applications of coagulation (that is, thrombus and hemostasis), chemiluminescence immunoassay (CLIA) and other fields, including POCT detection instruments, microfluidic control disc chips and supporting diagnostic reagents.

It is aimed to apply to the emergency departments of large hospitals, small and medium-sized hospitals, community grass-roots hospitals, clinical departments and new mobile medical diagnosis system and so on.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/04/16/pushkang-received-tens-of-millions-of-yuan-in-round-b-financing/.

Leave a Reply

Please Login to Comment